According to Orient's announcement, Yangzhou Orient Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received the “Drug Registration Certificate” for estradiol didrogestrel tablets approved and issued by the State Drug Administration. The drug is a hormone replacement therapy drug suitable for treating symptoms of estrogen deficiency in women at least 12 months after menopause. The registered classification is 4 types of chemicals, with specifications of 0.5 mg of estradiol and 2.5 mg of didroprogesterone. As of the announcement date, the company had invested a total of about 8.4875 million yuan in the drug research and development project. This approval has enriched the company's product pipeline in the field of women's health, which is conducive to enhancing market competitiveness in related fields.

Zhitongcaijing · 2d ago
According to Orient's announcement, Yangzhou Orient Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received the “Drug Registration Certificate” for estradiol didrogestrel tablets approved and issued by the State Drug Administration. The drug is a hormone replacement therapy drug suitable for treating symptoms of estrogen deficiency in women at least 12 months after menopause. The registered classification is 4 types of chemicals, with specifications of 0.5 mg of estradiol and 2.5 mg of didroprogesterone. As of the announcement date, the company had invested a total of about 8.4875 million yuan in the drug research and development project. This approval has enriched the company's product pipeline in the field of women's health, which is conducive to enhancing market competitiveness in related fields.